Janet L. Vaught v. Showa Denko K.K.

107 F.3d 1137, 37 Fed. R. Serv. 3d 134, 1997 U.S. App. LEXIS 4302, 1997 WL 104159
CourtCourt of Appeals for the Fifth Circuit
DecidedMarch 10, 1997
Docket96-20200
StatusPublished
Cited by75 cases

This text of 107 F.3d 1137 (Janet L. Vaught v. Showa Denko K.K.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Fifth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Janet L. Vaught v. Showa Denko K.K., 107 F.3d 1137, 37 Fed. R. Serv. 3d 134, 1997 U.S. App. LEXIS 4302, 1997 WL 104159 (5th Cir. 1997).

Opinion

RHESA HAWKINS BARKSDALE, Circuit Judge:

For this diversity action, the key issues at hand are when the limitations period began running under Texas law for the Vaughts’ cause of action arising out of Janet L. Vaught’s use of L-tryptophan, a nutritional supplement, and whether her membership in a putative federal class action in another State tolled the Texas limitations period until class certification was denied. Asserting, in *-445 ter alia, that a diligent, but fruitless, inquiry was made as to whether the Vaughts had a cause of action, the Vaughts challenge the summary judgment granted Defendants on limitations grounds. We AFFIRM.

I.

In August 1987, while hospitalized for injuries received in an automobile accident, Janet Vaught (Vaught) was prescribed L-trypto-phan, an over-the-counter nutritional supplement. She had never taken this product. After her hospitalization, however, she continued to take L-tryptophan for several months pursuant to prescription purchases. In late 1987 or early 1988, she began to experience various unexplained physical symptoms: fatigue, swollen neck glands, sore throats, body aches, burning sensations, tingling on her legs, and muscle and joint pain. She stopped taking L-tryptophan in December 1988, when she learned that she was pregnant.

On 4 April 1990, Vaught read a newspaper article about an action filed by a Houston, Texas, lawyer on behalf of a woman who allegedly contracted eosinophilia myalgia syndrome (EMS) from L-tryptophan. EMS is a multisystemic disorder characterized by severe muscle and joint pain, swelling of the arms and legs, skin rash, fever, and sometimes neuropathy, resulting in paralysis and death. In the fall of 1989, the Food and Drug Administration (FDA) established that over 280 cases of EMS were connected to the ingestion of L-tryptophan, a “virtually unequivocal” epidemiological link. As a result, the FDA issued a nationwide, mandatory recall of L-tryptophan in late November 1989.

Vaught noticed that she suffered some of the same symptoms that the newspaper article described as indicative of EMS, such as fatigue, stiffness, and muscle and joint pain. She contacted a paralegal (now the Vaughts’ lawyer) in the Houston lawyer’s office, to obtain information about EMS, although Vaught contends that she did not think she had EMS at that time. Her contact with that law firm led her to contact two doctors conducting an EMS study at Baylor University Medical School, Drs. Harati and McKinley.

Dr. McKinley sent her an “L-tryptophan Eosinophilia-Myalgia Patient Data Sheet”. When Vaught began filling out the questionnaire on 18 April 1990, she thought she might have EMS, so she called the Baylor doctors for their opinion. Vaught spoke with each of them at the end of April.

Also in April 1990, after reading the newspaper article, Vaught contacted Dr. Keichian, who had treated her for her automobile accident injuries, and told him that she had taken L-tryptophan. Dr. Keichian ordered a blood test, and on 25 April told Vaught that her eosinophil levels were normal and that she did not have EMS.

That June, Vaught arranged to have an examination done by one of the Baylor doctors, Dr. Harati. She brought her medical records and the completed Patient Data Sheet to the examination. Once again, she was advised that she had normal eosinophil levels in her blood and did not have EMS. Dr. Harati referred Vaught to Dr. Croock, a Baylor University rheumatologist, for further evaluation.

Vaught was examined by Dr. Croock on 13 July 1990; he told her that she was not suffering from EMS but from fibromyalgia or fibrositis. He gave Vaught information on fibromyalgia and prescribed Elavil, a tricyclic antidepressant used primarily for treating that ailment.

Vaught took Elavil for approximately six months, and her condition improved somewhat. Her symptoms, however, never completely disappeared, in spite of her attempts at other curative measures, such as physical therapy.

By the end of 1992, Vaught’s condition worsened; she experienced dizziness, fainting spells, and respiratory and gastrointestinal problems. In late 1992 or early 1993, she again became concerned that she might have EMS. She contacted her family physician, Dr. Fields. And in January 1993, she consulted Dr. Patton. That February and March, she underwent muscle and sural nerve biopsies to rule out EMS. Dr. Fields then recommended Vaught to Dr. Burns; in April 1993, he diagnosed EMS on the basis of *-444 Vaught’s biopsies, medical records, exams, and blood work.

Vaught contacted the paralegal with whom she had spoken in 1990 and who had become a practicing attorney in Houston. On 28 April 1993, Vaught and her husband filed this action in Texas state court against Showa Denko K.K. and its American distributors; it was removed to federal court in February 1994. That June, the Panel on Multidistrict Litigation ordered this action transferred to the United States District Court for the District of South Carolina to be joined with pending nationwide L-tryptophan litigation being conducted there (MDL No. 865). In September 1995, this action was conditionally remanded to district court in Texas for further proceedings.

Defendants then moved for summary judgment on limitations grounds. Following a hearing in January 1996, the district court granted the motion.

II.

The Vaughts present three issues. First, they contend that a genuine issue of material fact exists as to when their cause of action accrued. Next, they seek certification of the following question to the Texas Supreme Court: “Under the Texas discovery rule, does a plaintiffs diligent, but fruitless, inquiry into whether she has an actionable toxic tort suspend the statute of limitations running against her claim?”. Finally, they maintain that Janét Vaught’s membership in a putative nationwide L-tryptophan class action tolled the limitations period until class certification was denied.

We review a summary judgment de novo, applying the same standard as the district court. E.g., Bodenheimer v. PPG Indus., Inc., 5 F.3d 955, 956 (5th Cir.1993). Such judgment is appropriate where “there is no genuine issue as to any material fact and the movant is entitled to judgment as a matter of law”. Fed. R. Civ. P. 56(e). In making this determination, we are to draw all reasonable inferences in favor of the nonmovant. E.g., Bodenheimer, 5 F.3d at 956. And, because this is a diversity action, we apply Texas substantive law. Erie R.R. Co. v. Tompkins, 304 U.S. 64, 58 S.Ct. 817, 82 L.Ed. 1188 (1938).

A.

In Texas, a personal injury action must be filed “not later than two years after the day the cause of action accrues.” Tex. (Crv. Prao. & Rem.) Code Ann. § 16.003(a). Generally, accrual occurs on the date “the plaintiff first becomes entitled to sue the defendant based upon a legal wrong attributed to the latter”, even if the plaintiff is unaware of the injury. Zidell v. Bird,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
107 F.3d 1137, 37 Fed. R. Serv. 3d 134, 1997 U.S. App. LEXIS 4302, 1997 WL 104159, Counsel Stack Legal Research, https://law.counselstack.com/opinion/janet-l-vaught-v-showa-denko-kk-ca5-1997.